Survival and response outcomes in patients with recurrent/metastatic head and neck cancer treated with opioids and statins: an exploratory pilot study.

Transl Cancer Res · 2026 · PMC12885892 · PMID 41674961

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP=0.06so close (0.05 < p ≤ 0.1)

Interestingly, use of both drugs together was associated with improved ORR [odds ratio (OR) =2.8], and use of opioids without statins was associated with worse ORR (OR =0.34), though these results did not reach statistical significance (P=0.06).

also in 50,127 other papers

not quite statistically significantP=0.06so close (0.05 < p ≤ 0.1)

Opioid use without statin use trended toward worse ORR, again not quite statistically significant at P=0.06, suggesting that statins may somehow negate the negative impact of opioids.

also in 63 other papers

did not quite reach significanceP=0.08so close (0.05 < p ≤ 0.1)

OS had a similar trend as PFS in these groups, that also did not quite reach significance (HR =1.618 with 95% CI of 0.937 to 2.794, P=0.08), with a post-hoc power analysis indicating 79.5% power to detect a difference in 5-year survival of this magnitude with alpha of 0.05 ( Figure 3 ).

also in 60 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.